6.3 Peripheral Device Selection Criteria
Key Takeaways
- Select the least invasive peripheral device that safely meets therapy duration, infusate characteristics (osmolarity, pH, vesicant/irritant properties), and administration pattern (intermittent vs continuous).
- Preserve vessel health with stepwise escalation: short PIV → long peripheral/UGPIV → midline → central access only when therapy or duration demands it.
- Never choose a short PIV or midline for continuous vesicants or for extreme osmolarity/pH/TPN needs that require confirmed central tip location.
- Avoid using the antecubital fossa for long-term dwell when better forearm options exist; avoid ventral wrist sites due to nerve injury risk.
- Reassess device necessity daily—remove peripheral access that is no longer indicated to cut infection, phlebitis, and thrombosis risk.
Selection as a safety algorithm
CRNI Access Devices items rarely ask you to name a brand. They ask you to choose the right class of device for a therapy story. Section 6.3 integrates short PIV, long peripheral, and midline decision rules into one practical framework aligned with INS-minded vessel health preservation.
Quick Answer: Choose the lowest-risk, least invasive device that still matches (1) duration, (2) osmolarity/pH, (3) vesicant/irritant properties, and (4) intermittent vs continuous delivery. Escalate stepwise—short PIV → long peripheral/UGPIV → midline → CVAD—only as therapy demands. Midlines are not central. Continuous vesicants and many hyperosmolar/extreme pH/TPN therapies need central tips. Prefer forearm over AC for dwell; avoid ventral wrist.
The four therapy drivers
1. Duration of therapy
| Expected duration | Typical peripheral pathway thinking |
|---|---|
| Hours to a few days | Short PIV first-line if veins adequate |
| Several days with difficult veins | Long peripheral / UGPIV or early midline consideration |
| Days to weeks, peripheral-compatible | Midline often considered if short PIVs inadequate |
| Weeks to months, complex/central chemistry | Plan CVAD (PICC, tunneled, port) rather than serial midlines that do not fix chemistry limits |
Duration alone never overrides chemistry. A one-day continuous vesicant still needs an appropriate device class.
2. Osmolarity
Hyperosmolar infusions draw fluid from endothelial cells and inflame peripheral veins. Standards and drug references set thresholds and product-specific guidance for peripheral versus central administration. Exam principle: as osmolarity rises into ranges associated with high peripheral vein injury risk—especially for continuous infusion—central access becomes the safer default. Do not “stretch” a short PIV or midline to deliver PN or other highly hyperosmolar admixtures that policy assigns to central tips.
3. pH (acidity/alkalinity)
Extreme acidic or alkaline infusates chemically injure the intima. Peripheral veins tolerate a narrower chemical window than high-flow central veins. When references label a drug as requiring central administration due to pH, device selection follows the label/standards, not bedside convenience.
4. Vesicant and irritant properties
| Classification | Clinical concern | Device implication |
|---|---|---|
| Irritant | Pain/phlebitis along vein | May still be peripheral if policy allows; monitor closely; consider larger veins/central if poorly tolerated |
| Vesicant | Tissue necrosis if extravasated | Continuous vesicant → central access; do not use midline/short PIV as a loophole |
| Non-vesicant, peripheral-compatible | Standard infiltration risk | Short PIV, long peripheral, or midline by duration/veins |
Intermittent vs continuous: Continuous exposure multiplies chemical injury time and extravasation detection urgency. Intermittent dosing may be manageable peripherally for some agents under protocol; continuous vesicant infusion is a hard stop against midline/short PIV on exam items.
Stepwise escalation and vessel health preservation
Think of peripheral veins as a non-renewable resource for many chronically ill patients.
Escalation ladder (conceptual)
- Is IV therapy required at all? Prefer oral/NG/alternative routes when clinically equal.
- Short PIV in the best available forearm vein with smallest adequate gauge.
- Optimize short PIV success: warmth, proper lighting, expert inserter, limited attempts, vein visualization tools.
- Long peripheral / UGPIV for deeper peripheral targets when short PIVs fail but therapy remains peripheral-compatible.
- Midline for intermediate dwell peripheral-compatible therapy when repeated peripheral restarts harm the patient or vessels.
- CVAD when therapy chemistry, duration, or monitoring needs require central tip location—or when peripheral options are exhausted and still indicated.
Vessel preservation tactics
- Limit unsuccessful attempts; escalate skill level early (two-attempt culture with specialist referral as policy defines).
- Avoid dominant arm when possible if it does not compromise the better vein.
- Protect fistula arms, post-mastectomy/node-dissection arms, and infected limbs.
- Do not place “just in case” IVs without indication in vulnerable patients.
- Remove idle catheters promptly—every unnecessary day of dwell is avoidable risk.
- Document vein condition over time so the next clinician does not blindly re-stick phlebitic cords.
Matching device to scenario (decision table)
| Clinical picture | Prefer |
|---|---|
| Single bolus, good forearm vein, non-vesicant | Short PIV |
| 48-hour fluids/antibiotics, easy veins | Short PIV; clinically indicated removal |
| Difficult superficial veins, peripheral-compatible meds for several days | UGPIV / long peripheral |
| 10–14 days peripheral-compatible intermittent antibiotics, failed short PIVs | Midline candidate |
| Continuous vesicant chemotherapy | CVAD (not short PIV, not midline) |
| Hyperosmolar TPN requiring central admin | CVAD |
| Weeks of complex multi-therapy including central-only drugs | CVAD plan early |
| Easy AC stick in a patient needing 5-day continuous non-vesicant infusion | Seek forearm site instead of AC long dwell |
Site selection criteria within peripheral options
Even after choosing “short PIV,” site quality changes outcomes:
| Prefer | Avoid / minimize for dwell |
|---|---|
| Forearm straight veins | Antecubital fossa for multi-day continuous therapy |
| Areas away from flexion | Ventral wrist (nerve injury) |
| Intact skin, non-infected | Areas of phlebitis, infiltration, hematoma, burns |
| Upper extremity in adults | Routine lower extremity adult access |
| Adequate vein diameter for gauge | Fragile vein with oversized catheter |
AC fossa exam trap: The median cubital vein is large and seductive for first-stick success, but joint motion makes it a poor long-term infusion site. Acceptable for emergencies, short procedures, or when no alternative exists—not the default multi-day continuous site.
Integrating ultrasound and specialist teams
Ultrasound is a selection enabler, not a device class:
- UGPIV can make a short or long peripheral succeed without escalating to midline.
- Ultrasound for midline/PICC still requires correct length and tip target for the intended device.
- Vascular access teams improve first-stick success and appropriate escalation—use them when available rather than exhausting every distal vein.
Risk–benefit communication
Device selection includes informed discussion:
- Why this device class matches the ordered therapy
- Alternatives (including oral switch if appropriate)
- Risks: phlebitis, infiltration/extravasation, thrombosis, infection, insertion discomfort
- Patient preferences (arm choice, fear of needles, home care capability for midline/PICC)
Document the rationale when choosing midline over serial PIVs or when escalating to PICC because of vesicant/osmolarity needs.
Daily reassessment checklist
Use this mental checklist each shift:
- Is the catheter still indicated?
- Is the therapy still compatible with this device class?
- Is the site healthy (no infiltration, phlebitis meeting removal criteria, leakage, purulence)?
- Is the device functional (flush, blood return as expected, no unresolved occlusion)?
- Would a different device now better match an evolving plan (e.g., new vesicant order)?
If a patient starts on short PIV antibiotics and the plan changes to continuous vesicant therapy, re-select the device—do not keep the short PIV because “access is already there.”
Putting it together: two full vignettes
Vignette 1: 45-year-old with cellulitis needs 7 days of intermittent peripheral-compatible IV antibiotics, then oral step-down. Forearm vein available. Select short PIV, educate on site care, assess every shift, remove when converted to oral or if complications occur. No midline required solely for a week if peripheral access is reliable.
Vignette 2: 68-year-old with poor superficial veins needs 12 days of peripheral-compatible IV antibiotics; three short PIV failures overnight; no vesicant; no PN. Ultrasound shows upper-arm vein suitable for midline. Midline is reasonable to preserve vessels and complete therapy. If orders later add continuous vesicant or central-only PN, escalate to PICC/other CVAD—do not stretch the midline.
High-yield exam traps (selection-focused)
- Calling a midline a central line and using it for central-only therapies
- Infusing continuous vesicants via midline or short PIV
- Using the AC fossa long-term because insertion was easy
- Skipping stepwise thinking and placing a PICC for every multi-day antibiotic without evaluating peripheral suitability
- Leaving idle peripheral devices in place “for convenience”
- Choosing gauge/site by habit instead of therapy and vessel health
Summary decision mantra
Right drug → right duration → right vein → right device tip location → right time to remove. If any element changes, re-run the algorithm. That mantra is the clinical and CRNI selection standard for peripheral venous access devices.
Which factor set should drive peripheral device selection most directly?
A patient will receive continuous vesicant chemotherapy. Which access plan is appropriate?
Which example best demonstrates vessel-health-preserving stepwise escalation?
Why is the antecubital fossa generally a poor choice for multi-day continuous peripheral infusion when forearm veins are available?